Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

Chang‐Claude, Jenny; Wooten, Eric C.; Tsimelzon, Anna; Hilsenbeck, Susan G.; Gutierrez, Maya; Elledge, Richard M.; Mohsin, Syed K.; Osborne, C. Kent; Chamness, Gary C.; Allred, D. Craig; O’Connell, P.

doi:10.1016/s0140-6736(03)14023-8

Cited by 763 publications

(474 citation statements)

References 23 publications

Supporting

Mentioning

445

Contrasting

Unclassified

Order By: Relevance

“…Gene 'signatures' or predictors have been devised for several chemotherapy regimens, including paclitaxel followed by fluorouracil, AC, AC/doxorubicindocetaxel and taxane only chemotherapy (Chang et al, 2003(Chang et al, , 2005bAyers et al, 2004;Hannemann et al, 2005;Cleator et al, 2006). Although these results are promising, the exceedingly small sample size and limitations with the current technology and analysis methods have so far precluded definitive conclusions (Brenton et al, 2005;Reis-Filho et al, 2006b).…”

Section: Discussionmentioning

confidence: 99%

“…The use of expression arrays to derive molecular profiles that are predictive of clinical outcome has received great attention in the last 5 years (van't Veer et al, 2005;Reis-Filho et al, 2006b), especially in the neoadjuvant setting (Davidson and Morrow, 2005). Predictive signatures for different neoadjuvant chemotherapy regimens have been reported by some investigators but with less success by others (Chang et al, 2003;Ayers et al, 2004;Cleator and Ashworth, 2004;Chang et al, 2005a;Hannemann et al, 2005;Iwao-Koizumi et al, 2005;Modlich et al, 2005;Rouzier et al, 2005;Dressman et al, 2006;Reis-Filho et al, 2006b). Although some of these results are promising, issues related to the instability of mRNA, experimental design and data analysis have led many to call into question the validity of current approaches (Ransohoff, 2004;Brenton et al, 2005;Ioannidis, 2005;Reis-Filho et al, 2006b).…”

mentioning

confidence: 99%

See 1 more Smart Citation

Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy

et al. 2006

View full text Add to dashboard Cite

We analysed the molecular genetic profiles of breast cancer samples before and after neoadjuvant chemotherapy with combination doxorubicin and cyclophosphamide (AC). DNA was obtained from microdissected frozen breast core biopsies from 44 patients before chemotherapy. Additional samples were obtained before the second course of chemotherapy (D21) and after the completion of the treatment (surgical specimens) in 17 and 21 patients, respectively. Microarray-based comparative genome hybridisation was performed using a platform containing B5800 bacterial artificial chromosome clones (genome-wide resolution: 0.9 Mb). Analysis of the 44 pretreatment biopsies revealed that losses of 4p, 4q, 5q, 12q13.11 -12q13.12, 17p11.2 and 17q11.2; and gains of 1p, 2p, 7q, 9p, 11q, 19p and 19q were significantly associated with oestrogen receptor negativity. 16q21 -q22.1 losses were associated with lobular and 8q24 gains with ductal types. Losses of 5q33.3 -q4 and 18p11.31 and gains of 6p25.1 -p25.2 and Xp11.4 were associated with HER2 amplification. No correlations between DNA copy number changes and clinical response to AC were found. Microarray-based comparative genome hybridisation analysis of matched pretreatment and D21 biopsies failed to identify statistically significant differences, whereas a comparison between matched pretreatment and surgical samples revealed a statistically significant acquired copy number gain on 11p15.2 -11p15.5. The modest chemotherapy-driven genomic changes, despite profound loss of cell numbers, suggest that there is little therapeutic selection of resistant non-modal cell lineages.

show abstract

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy

et al. 2006

View full text Add to dashboard Cite

show abstract

“…From each core biopsy, sufficient total RNA was extracted for oligonucleotide array analysis and preliminary patterns predictive of sensitivity and resistance to specific treatments have been reported (Chang et al, 2003), where others report 45% (Buchholz et al, 2002) or as high as 93% (Ellis et al, 2002) of core biopsies to yield sufficient high-quality RNA for array analysis. Other investigators have reported faithful linear RNA amplification protocols using limited amounts of RNA from microdissected breast tissues (Aoyagi et al, 2003).…”

Section: Microarray Analysis To Identify Predictive Biomarkersmentioning

confidence: 99%

Genomic approaches in the management and treatment of breast cancer

2005

View full text Add to dashboard Cite

Breast cancer is the most common malignancy afflicting women from Western cultures. It has been estimated that approximately 211 000 women will be diagnosed with breast cancer in 2003 in the United States alone, and each year over 40 000 women will die of this disease. Developments in breast cancer molecular and cellular biology research have brought us closer to understanding the genetic basis of this disease. Unfortunately, this information has not yet been incorporated into the routine diagnosis and treatment of breast cancer in the clinic. Recent advancements in microarray technology hold the promise of further increasing our understanding of the complexity and heterogeneity of this disease, and providing new avenues for the prognostication and prediction of breast cancer outcomes. The most recent application of microarray genomic technologies to studying breast cancer will be the focus of this review. Mortality from breast cancer results from the ability of some tumours to metastasise to distant sites. Selecting patients with micrometastases at diagnosis is crucial for clinicians in deciding who should and who should not receive toxic and expensive adjuvant chemotherapy to eradicate these metastatic cells. Axillary nodal status, the best marker now available, is still an imperfect indicator, since about 25% of node-negative patients do harbour micrometastases and are destined to recur, while up to 25% of node-positive patients will not recur even without adjuvant treatment after many years of follow-up. In spite of extensive studies, expression of most individual genes has not proven powerful enough for routine clinical use to predict accurately distant metastases over the lifetime of an individual patient. However, recent developments in applying microarray technologies to breast tumour samples suggest that these new techniques may provide for the transition of molecular biological discoveries to clinical application, and will generate clinically useful genomic profiles that more accurately predict long-term outcome of individual breast cancer patients. NATURAL HISTORY OF BREAST CANCERBreast cancer is characterised by a very heterogeneous clinical course. A major goal of recent studies is to determine whether RNA microarray expression profiling, or DNA array gene amplification/gene loss patterns, can accurately predict an individual's long-term potential for recurrence from breast cancer, so that appropriate treatment decisions can be made. It is well established that some aspects of breast cancer heterogeneity is related to the different risk factors for diagnosis of this disease, such as race, diet, age, environmental factors, and cumulative exposure to the sex hormone oestrogen. The diversity in clinical course of breast cancer is undoubtedly related to differences in tumour growth rates, tumour invasiveness, metastatic potential, and other complex cellular growth signalling and survival pathways. It has long been held that knowledge of these various biological factors would help individualise patient t...

show abstract

“…Preliminary data published in this area are promising but are hampered, as is frequently the case, by small sample size (Sotiriou et al, 2002;Chang et al, 2003;Pusztai et al, 2003). In the largest of these studies, Chang et al performed expression arrays on samples from 24 patients, 11 of which were classified as chemosensitive and 13 of which were classified as chemoresistant.…”

Section: Predicting Chemotherapy Responsementioning

confidence: 99%

Molecular profiling of breast cancer: clinical implications

Cleator

Ashworth

2004

Br J Cancer

View full text Add to dashboard Cite

Breast cancers are routinely subcategorised on the basis of clinical stage, cellular morphology and immunohistochemical analysis of a small number of markers. The recent development of gene expression microarray and related technologies provides an opportunity to perform more detailed profiling of the disease. It is anticipated that the molecular classification arising from such studies will be more powerful than its pathological predecessor at confining treatment to those patients who are most likely to benefit. It is likely that this will result in a much less frequent use of adjuvant chemotherapy. Furthermore, of those who do receive it, a higher proportion will benefit. If adopted, this will offer considerable patient benefits in terms of reducing unnecessary toxicity and have major health economic implications.

show abstract

Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer

Cited by 763 publications

References 23 publications

Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy

Microarray-based comparative genomic hybridisation of breast cancer patients receiving neoadjuvant chemotherapy

Genomic approaches in the management and treatment of breast cancer

Molecular profiling of breast cancer: clinical implications

Contact Info

Product

Resources

About